Brain47Brain47Join Brain47
2HA

Spero Therapeutics Inc.

Healthcare · EUR · F

2HA

Price

€2.304

+6.67%

Cap

€148.23M

Earnings

—

30d Trend

-1.8%

2HA
Loading chart data...
0 days · % change from startPowered by Brain47

BRAIN47 SIGNAL

0
MODERATE
Risk Level80
Quality40
Momentum66
Technical57
Fundamentals59

Raw weighted: 52×Macro 0.99 (−1%)=51

RISK

80/100
90d Volatility
50.6%High
ATR %
5.5%High daily moves
Max Drawdown (1Y)
-39.8%Volatile

QUALITY

40/100
ROE (avg)
14.5%Good
Piotroski F-Score
4/9Average
Accruals
30.8%Accrual heavy

MOMENTUM

66/100
12-1M Momentum
+14.9%Strong uptrend
6-1M Momentum
+12.3%Positive
1M Return
+9.7%Strong recent gains
Relative Strength
+0.2% vs sectorIn-line

TECHNICAL

57/100
RSI (14)
64.4Neutral
Price vs SMA200
+25.2%Bullish trend
MACD
+0.03Bullish momentum
Bollinger Band
107%Near upper band
SMA Cross
Death CrossDeath Cross
Trend Quality (KER)
0.173Noisy/choppy

FUNDAMENTALS

59/100
EV/EBIT
18.2Fair
P/S
2.3Fair

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months65
3-12 months ★80
1-5+ years50

6-9 month momentum thesis — strong trend with confirmation

BRAIN47'S ASSESSMENT

I rate Spero Therapeutics Inc. at 51/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 66/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.

DETAILED ANALYSIS

6-9 month momentum thesis — strong trend with confirmation. Momentum (66) and Fundamentals (59) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. I classify this as a growth position — strong momentum combined with solid fundamentals points to capital appreciation.

growthScore: 51/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.